Cargando…
A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Te...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908639/ https://www.ncbi.nlm.nih.gov/pubmed/34218336 http://dx.doi.org/10.1007/s00787-021-01837-z |
_version_ | 1784884407521247232 |
---|---|
author | Johnson, Mats Gillberg, Carina Vinsa, Ingrid Fransson, Gunnar Samuelsson, Lena Jakobsson, Klara Östlund, Sven Fernell, Elisabeth Gillberg, Christopher |
author_facet | Johnson, Mats Gillberg, Carina Vinsa, Ingrid Fransson, Gunnar Samuelsson, Lena Jakobsson, Klara Östlund, Sven Fernell, Elisabeth Gillberg, Christopher |
author_sort | Johnson, Mats |
collection | PubMed |
description | The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Ten-week randomized controlled trial of PR-ESSENCE for children and adolescents aged 5–18 years, compared to treatment as usual. Outcomes were assessed at baseline and randomized period endpoint. Primary outcome was the Clinical Global Impression—Improvement scale (CGI-I) rated by blinded assessors. Secondary outcomes were rated by parents—SNAP-IV, Eyberg Child Behavior Inventory (ECBI), Relationship Problems Questionnaire, Family Burden of Illness Module, and children—Beck Youth Inventories (BYI). ClinicalTrials.gov identifier: NCT03780413. The study enrolled 108 participants (active n = 72; controls n = 36, randomized 2:1), of whom 95 completed the randomized period. No clinically significant group differences were found in baseline characteristics. More than half had autism and 80% had ADD or ADHD. Large treatment effects were seen on CGI-I (ITT analysis, Effect Size 1.48). Treatment responders, much/very much improved on CGI-I, were 51.4% in active group and 5.6% of controls. Effect sizes were medium to large in parent ratings on SNAP-IV (ODD and ADHD symptoms), ECBI (behaviour problems), and in BYI child self-ratings of disruptive behaviour. PR-ESSENCE treatment improved global symptoms and functioning (CGI-I), behaviour problems, ADHD and ODD symptoms, and disruptive behaviour. Treatment effects were at least equivalent to those in previous studies of well-established Parent Management Training and Collaborative Problem Solving programs. |
format | Online Article Text |
id | pubmed-9908639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-99086392023-02-10 A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE Johnson, Mats Gillberg, Carina Vinsa, Ingrid Fransson, Gunnar Samuelsson, Lena Jakobsson, Klara Östlund, Sven Fernell, Elisabeth Gillberg, Christopher Eur Child Adolesc Psychiatry Original Contribution The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Ten-week randomized controlled trial of PR-ESSENCE for children and adolescents aged 5–18 years, compared to treatment as usual. Outcomes were assessed at baseline and randomized period endpoint. Primary outcome was the Clinical Global Impression—Improvement scale (CGI-I) rated by blinded assessors. Secondary outcomes were rated by parents—SNAP-IV, Eyberg Child Behavior Inventory (ECBI), Relationship Problems Questionnaire, Family Burden of Illness Module, and children—Beck Youth Inventories (BYI). ClinicalTrials.gov identifier: NCT03780413. The study enrolled 108 participants (active n = 72; controls n = 36, randomized 2:1), of whom 95 completed the randomized period. No clinically significant group differences were found in baseline characteristics. More than half had autism and 80% had ADD or ADHD. Large treatment effects were seen on CGI-I (ITT analysis, Effect Size 1.48). Treatment responders, much/very much improved on CGI-I, were 51.4% in active group and 5.6% of controls. Effect sizes were medium to large in parent ratings on SNAP-IV (ODD and ADHD symptoms), ECBI (behaviour problems), and in BYI child self-ratings of disruptive behaviour. PR-ESSENCE treatment improved global symptoms and functioning (CGI-I), behaviour problems, ADHD and ODD symptoms, and disruptive behaviour. Treatment effects were at least equivalent to those in previous studies of well-established Parent Management Training and Collaborative Problem Solving programs. Springer Berlin Heidelberg 2021-07-03 2023 /pmc/articles/PMC9908639/ /pubmed/34218336 http://dx.doi.org/10.1007/s00787-021-01837-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contribution Johnson, Mats Gillberg, Carina Vinsa, Ingrid Fransson, Gunnar Samuelsson, Lena Jakobsson, Klara Östlund, Sven Fernell, Elisabeth Gillberg, Christopher A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title | A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title_full | A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title_fullStr | A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title_full_unstemmed | A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title_short | A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE |
title_sort | randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: pr-essence |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908639/ https://www.ncbi.nlm.nih.gov/pubmed/34218336 http://dx.doi.org/10.1007/s00787-021-01837-z |
work_keys_str_mv | AT johnsonmats arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT gillbergcarina arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT vinsaingrid arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT franssongunnar arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT samuelssonlena arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT jakobssonklara arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT ostlundsven arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT fernellelisabeth arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT gillbergchristopher arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT johnsonmats randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT gillbergcarina randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT vinsaingrid randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT franssongunnar randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT samuelssonlena randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT jakobssonklara randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT ostlundsven randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT fernellelisabeth randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence AT gillbergchristopher randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence |